These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36944332)

  • 41. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of cancer-associated mutations in Hsh155/SF3b1 HEAT repeats 9-12 on pre-mRNA splicing in Saccharomyces cerevisiae.
    Kaur H; Groubert B; Paulson JC; McMillan S; Hoskins AA
    PLoS One; 2020; 15(4):e0229315. PubMed ID: 32320410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
    Xiong B; Xue M; Yu Y; Wu S; Zuo X
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
    Choi IY; Ling JP; Zhang J; Helmenstine E; Walter W; Tsakiroglou P; Bergman RE; Philippe C; Manley JL; Rouault-Pierre K; Li B; Wiseman DH; Batta K; Ouseph M; Bernard E; Dubner B; Li X; Haferlach T; Koget A; Fazal S; Jain T; Gocke CD; DeZern AE; Dalton WB
    Blood Adv; 2024 Aug; 8(15):3961-3971. PubMed ID: 38759096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
    Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
    Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
    Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
    Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
    [No Abstract]   [Full Text] [Related]  

  • 49. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
    Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
    J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-mutation of
    Song J; Moscinski L; Yang E; Shao H; Hussaini M; Zhang H
    In Vivo; 2023; 37(3):985-993. PubMed ID: 37103105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
    Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
    Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
    Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
    Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The significance of spliceosome mutations in chronic lymphocytic leukemia.
    Rozovski U; Keating M; Estrov Z
    Leuk Lymphoma; 2013 Jul; 54(7):1364-6. PubMed ID: 23270583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition.
    Sarchi M; Clough CA; Crosse EI; Kim J; Baquero Galvis LD; Aydinyan N; Wellington R; Yang F; Gallì A; Creamer JP; Stewart S; Bradley RK; Malcovati L; Doulatov S
    Blood Cancer Discov; 2024 Sep; 5(5):353-370. PubMed ID: 38856693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
    Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
    Liu B; Liu Z; Chen S; Ki M; Erickson C; Reis-Filho JS; Durham BH; Chang Q; de Stanchina E; Sun Y; Rabadan R; Abdel-Wahab O; Chandarlapaty S
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33031100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
    Kataoka N; Matsumoto E; Masaki S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.